跳至主要内容
临床试验/NCT02328807
NCT02328807已完成不适用

Focal Prostate Radio-Frequency Ablation for the Treatment of Prostate Cancer

H. Lee Moffitt Cancer Center and Research Institute2 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2014年12月29日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
6
试验地点
2
主要终点
Negative Biopsy Rate at 6 Months After Focal Bipolar Radio-Frequency Ablation (RFA)

研究概览

简要总结

The main purpose of this study is to evaluate the safety and efficacy of focal (targeted) Radio-Frequency Ablation (RFA) in men with low or intermediate-risk, clinically localized prostate cancer.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Men 18 years of age or older
  • Diagnosis of adenocarcinoma of the prostate, confirmed by H.L. Moffitt Cancer Center review
  • No prior treatment for prostate cancer
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or1
  • Prostate Cancer Clinical Stage T2a and below
  • PSA <10 ng/ml (this will be the prostatic specific antigen (PSA) level prompting the initial prostate biopsy)
  • Prostate size <60 cc on transrectal ultrasound
  • Pre-enrollment biopsy parameters (as per H.L. Moffitt C.C. review): Minimum of 10 biopsy cores; Gleason score 6 aor 7; Unilateral cancer (only right-sided or left-sided, not bilateral).

排除标准

  • Men less than 18 years of age
  • Medically unfit for anesthesia
  • Histology other than adenocarcinoma
  • Biopsy does not meet inclusion criteria
  • Men who have received any hormonal manipulation (antiandrogens; Luteinizing Hormone Releasing Hormone (LHRH) agonist; 5-alpha-reductase inhibitors) within the previous 6 months

结局指标

主要结局

Negative Biopsy Rate at 6 Months After Focal Bipolar Radio-Frequency Ablation (RFA)

时间窗: 6 months

The primary efficacy endpoint is negative biopsy rate at 6 months after focal bipolar RFA. The point estimate and its 95% confidence interval will be calculated using the exact binominal method.

次要结局

  • Completion of Quality of Life (QOL) Assessment Questionnaires at Six Months(6 months)
  • Number of Participants With Treatment Related Adverse Events(Up to 9 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验